Jiajie Zhang

1838 North Guangzhou Boulevard
Guangzhou, 510515, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 57 publications

Novel 2-amino-4-(1H-imidazol)pyridine derivatives as potent brain-penetrant EGFR mutant inhibitors: Design, synthesis, biological evaluation, and molecular modeling study.

Novel 2-amino-4-(1H-imidazol)pyridine derivatives as potent brain-penetrant EGFR mutant inhibitors: Design, synthesis, biological evaluation, and molecular modeling study.

Journal: Bioorganic chemistry

Published: June 09, 2026

Clinicopathological and molecular characterization of HPV-associated cervical poorly cohesive carcinoma: a rare aggressive entity.

Clinicopathological and molecular characterization of HPV-associated cervical poorly cohesive carcinoma: a rare aggressive entity.

Journal: The journal of pathology. Clinical research

Published: February 28, 2026

Discovering potent EGFR inhibitors through the structural optimization of the Betti-base scaffold.

Discovering potent EGFR inhibitors through the structural optimization of the Betti-base scaffold.

Journal: Bioorganic & medicinal chemistry letters

Published: January 25, 2026

Peripheral regional anesthesia alleviates skeletal muscle injury and inflammation caused by acute compartment syndrome by inhibiting PI3K/AKT/NF-kB pathway and regulating macrophage polarization.

Peripheral regional anesthesia alleviates skeletal muscle injury and inflammation caused by acute compartment syndrome by inhibiting PI3K/AKT/NF-kB pathway and regulating macrophage polarization.

Journal: Cellular signalling

Published: January 08, 2026

Discovery of novel 3-Benzyloxyaminopyridines as orally available and intracranially active selective ROS1 inhibitors for combating the resistant ROS1G2032R mutation.

Discovery of novel 3-Benzyloxyaminopyridines as orally available and intracranially active selective ROS1 inhibitors for combating the resistant ROS1G2032R mutation.

Journal: European journal of medicinal chemistry

Published: June 04, 2025

Identification of novel selective estrogen receptor degraders (SERD) via physics-based and deep-learning-based virtual screening and Bioassys.

Identification of novel selective estrogen receptor degraders (SERD) via physics-based and deep-learning-based virtual screening and Bioassys.

Journal: Bioorganic chemistry

Published: April 25, 2025

Supramolecular hydrogel mediated photoelectrochemical/electrochemiluminescence dual-mode biosensor based on TiO2/CdIn2S4/CdS for sensitive detection of enrofloxacin.

Supramolecular hydrogel mediated photoelectrochemical/electrochemiluminescence dual-mode biosensor based on TiO2/CdIn2S4/CdS for sensitive detection of enrofloxacin.

Journal: Biosensors & bioelectronics

Published: March 28, 2025

Design and synthesis of Betti base derivatives as EGFR inhibitors.

Design and synthesis of Betti base derivatives as EGFR inhibitors.

Journal: Bioorganic chemistry

Published: March 25, 2025

Discovery of 3-phenyl-[1,2,4]triazolo[4,3-a]pyridine derivatives as potent smoothened inhibitors against colorectal carcinoma.

Discovery of 3-phenyl-[1,2,4]triazolo[4,3-a]pyridine derivatives as potent smoothened inhibitors against colorectal carcinoma.

Journal: Bioorganic & medicinal chemistry

Published: December 10, 2024

Discovery of novel Macrocyclic small molecules Based on 2-Amino-4-thiazolylpyridineas selective EGFR inhibitors with high Blood-Brain barrier penetration for the treatment of glioblastoma.

Discovery of novel Macrocyclic small molecules Based on 2-Amino-4-thiazolylpyridineas selective EGFR inhibitors with high Blood-Brain barrier penetration for the treatment of glioblastoma.

Journal: Bioorganic chemistry

Published: September 16, 2024

Design, synthesis and bioactivity evaluation of isobavachin derivatives as hURAT1 inhibitors for hyperuricemia agents.

Design, synthesis and bioactivity evaluation of isobavachin derivatives as hURAT1 inhibitors for hyperuricemia agents.

Journal: European journal of medicinal chemistry

Published: June 26, 2024

Discovery of Novel Small-Molecule-Based Potential PD-L1/EGFR Dual Inhibitors with High Druggability for Glioblastoma Immunotherapy.

Discovery of Novel Small-Molecule-Based Potential PD-L1/EGFR Dual Inhibitors with High Druggability for Glioblastoma Immunotherapy.

Journal: Journal of medicinal chemistry

Published: May 13, 2024

Showing 1-12 of 57

Last Updated: 09/26/2026